Trial · NCT01646177
Participant flow144
How many started, completed or left each group, period by period.
1 to 20 of 144
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Blinded Induction Dosing (Week 0-12) | STARTED | Placebo | 193 | |
| Blinded Induction Dosing (Week 0-12) | STARTED | 50 mg Etanercept (ETN) | 382 | |
| Blinded Induction Dosing (Week 0-12) | STARTED | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 386 | |
| Blinded Induction Dosing (Week 0-12) | STARTED | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) | 385 | |
| Blinded Induction Dosing (Week 0-12) | STARTED | PBO/IXE80Q4W | 0 | |
| Blinded Induction Dosing (Week 0-12) | STARTED | ETN/IXE80Q4W | 0 | |
| Blinded Induction Dosing (Week 0-12) | STARTED | IXE80Q4W/IXE80Q4W | 0 | |
| Blinded Induction Dosing (Week 0-12) | STARTED | IXE80Q2W/IXE80Q4W | 0 | |
| Blinded Induction Dosing (Week 0-12) | STARTED | PBO Follow-Up Period | 0 | |
| Blinded Induction Dosing (Week 0-12) | STARTED | ETN Follow-Up Period | 0 | |
| Blinded Induction Dosing (Week 0-12) | STARTED | IXE80Q4W Follow-Up Period | 0 | |
| Blinded Induction Dosing (Week 0-12) | STARTED | IXE80Q2W Follow-Up Period | 0 | |
| Blinded Induction Dosing (Week 0-12) | Received at Least One Dose of Study Drug | Placebo | 193 | |
| Blinded Induction Dosing (Week 0-12) | Received at Least One Dose of Study Drug | 50 mg Etanercept (ETN) | 382 | |
| Blinded Induction Dosing (Week 0-12) | Received at Least One Dose of Study Drug | 80 mg Ixekizumab Dosing Regimen 2 (Q4W) | 382 | |
| Blinded Induction Dosing (Week 0-12) | Received at Least One Dose of Study Drug | 80 mg Ixekizumab Dosing Regimen 1 (Q2W) | 384 | |
| Blinded Induction Dosing (Week 0-12) | Received at Least One Dose of Study Drug | PBO/IXE80Q4W | 0 | |
| Blinded Induction Dosing (Week 0-12) | Received at Least One Dose of Study Drug | ETN/IXE80Q4W | 0 | |
| Blinded Induction Dosing (Week 0-12) | Received at Least One Dose of Study Drug | IXE80Q4W/IXE80Q4W | 0 | |
| Blinded Induction Dosing (Week 0-12) | Received at Least One Dose of Study Drug | IXE80Q2W/IXE80Q4W | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01646177/flow